Clinical trial
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea…
NCT00154375 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00154375 |
|---|---|
| Title | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma |
| Official title | Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Astrocytoma |
| Intervention type | Drug |
| Interventions | Imatinib mesylate, Hydroxyurea |
| Enrollment | 240 |
| Start date | Oct 1, 2004 |
| Primary completion | Aug 1, 2008 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 26, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: